Abstract P6-10-01: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)CF Singer, G Michael, Georg Pfeiler et al.|Cancer Research|2017Cited by 2
Abstract P1-09-10: Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancerCF Singer, Angelika Reiner, M. Rudas et al.|Cancer Research|2017Cited by 2
Abstract P4-08-05: Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 yearsMartin Filipits, Michael Gnant, P Dubsky et al.|Cancer Research|2019Cited by 2